Dupixent® (dupilumab)

Dupixent is covered only for its FDA‑approved indications (atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, COPD, and chronic spontaneous urticaria) when patients meet indication‑specific age/weight cutoffs and clinical criteria; use that does not meet those criteria is excluded. Key requirements include documented prior therapy trials (e.g., topical corticosteroids for AD; ICS+additional controller for asthma; specified controller regimens for COPD), indication‑specific lab/biopsy thresholds (blood eosinophils, ≥15 eos/hpf for EoE), prescriber specialty involvement, specified initial/renewal durations, and documented clinical response for reauthorization.

"Atopic Dermatitis: Dupixent is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate to severe atopic dermatitis whose disease is not adequately controll..."